Reyna et al. develop BTSA1, a pharmacologically optimized BAX activator, which leads to sustained BAX-mediated apoptosis in leukemia cell lines and in AML xenografts, providing a novel therapeutic strategy in AML [88]. Here, BAX is linked to leukemia.